TASK Applied Science
11
2
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.4% vs industry average
9%
1 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis
Role: lead
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
Role: collaborator
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
Role: collaborator
A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098
Role: lead
A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide
Role: lead
EBA, Safety and Tolerability of Sanfetrinem Cilexetil
Role: lead
Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.
Role: collaborator
Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
Role: lead
BCG Vaccination for Healthcare Workers in COVID-19 Pandemic
Role: lead
Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB
Role: lead
Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
Role: lead
All 11 trials loaded